TELEFLEX Business Summary

Teleflex Inc. (TFX) is a global provider of medical technologies that generates revenue primarily through the sale of single-use medical devices and consumables to hospitals and healthcare providers. As of early 2026, the company is executing a major strategic pivot to focus on high-growth, high-acuity markets, having entered into definitive agreements to divest its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion. Its core remaining operations are concentrated in three primary segments: Vascular Access, Interventional, and Surgical. These segments leverage market-leading brands such as Arrow, EZ-IO, and Weck to maintain dominant positions in niches like central venous catheters and intraosseous access. Teleflex competes directly with diversified medtech giants such as Boston Scientific, Becton Dickinson (BD), and Integra LifeSciences, positioning itself as a specialized leader in procedural tools with high clinical stickiness and recurring revenue streams. Originally founded in 1943 by an engineer and a surgeon, Teleflex is currently led by Interim President and CEO Stuart Randle, who was appointed in January 2026 following the departure of Liam Kelly. Randle brings over 35 years of medical device leadership, including previous CEO roles at Ivenix and GI Dynamics. The executive team includes Executive Vice President and CFO John R. Deren, who assumed the role in April 2025 after a long tenure within the company’s finance organization. Dr. Stephen Klasko, a prominent healthcare executive and former CEO of Jefferson Health, serves as the Chairman of the Board. The company maintains a strong institutional investor base, with significant holdings by major firms including Janus Henderson Group, T. Rowe Price, and The Vanguard Group.